Basic information and pharmacological effects of Vigabatrin (Okeda)

Vigabatrin (Vigabatrin) is an anti-epileptic drug that belongs to the gamma-aminobutyric acid (GABA) analogue. It is mainly used to treat refractory epilepsy and infantile spasms. The drug was first launched in Europe and is currently approved for clinical use in many countries and regions. Vigabatrin is unique in that it enhances the inhibitory effect of GABA in the brain through an irreversible mechanism, thereby controlling epileptic seizures and having good efficacy in some patients who are ineffective with traditional anti-epileptic drugs.

In terms of pharmacological mechanism, the main function of Vigabatrin is to selectively and irreversibly inhibit GABA transaminase (GABA transaminase). This enzyme is the key enzyme responsible for breaking down GABA. When it is inhibited, the concentration of GABA in the brain increases significantly, thereby enhancing the inhibitory signals of the central nervous system. Since epileptic seizures are usually associated with excessive discharge and increased excitability of neurons, Vigabatrin can effectively inhibit abnormal neuronal discharge by increasing GABA levels to achieve anti-epileptic effects.

VigabatrinIt is clinically indicated for the treatment of complex partial epilepsy (especially in patients who do not respond well to other drugs) and infantile spasms. For infantile spasms, Vigabatrin has been shown to reduce or eliminate spasms in a short period of time, improving outcomes for children with the disease. In adults, this drug is often used as an adjunct in combination with other antiepileptic drugs to improve overall efficacy. It has a rapid onset of action, and some patients can observe a significant decrease in the frequency of epileptic seizures within a few days.

However, Vigabatrin also has certain risks during its application, especially its toxic effects on the retina, which may lead to irreversible visual field loss. Therefore, strict ophthalmic monitoring is required during use, especially in patients with long-term use. In addition, doctors usually weigh the pros and cons based on the patient's condition and carefully select the applicable population. Overall, Vigabatrin, as an antiepileptic drug with a unique mechanism, has important clinical value in the treatment of refractory epilepsy and infantile spasms.

Reference link:https://www.drugs.com